House leaders are balancing the need to win votes from conservative members with the need to not put moderate members at risk.
As House Republican leaders and President Donald Trump scramble for the last of the votes they need to pass the latest version of the American Health Care Act (AHCA), the word is out: it’s coming down to whether Republicans try to strip the essential health benefits out of the Affordable Care Act (ACA).
The essential health benefits are coverage for 10 core areas—including mental health and preventive care—that are required in marketplace plans under the ACA. Until now, Republicans have stayed away from trying to carve them out of the AHCA, since it hinges on a budget resolution. Go too far beyond what relates directly to the budget, and the Senate parliamentarian could say it’s beyond the scope of what’s allowed under a vote not subject to the Senate filibuster rules.
But keep the essential health benefits in, and the House Republicans risk losing members of the Freedom Caucus, the hard-right conservative members who object to the essential health benefits on 2 grounds: first, they represent the overregulation they dislike about “Obamacare,” and second, they drive up the cost of premiums and out-of-pocket expenses.
However, stripping out the essential health benefits has House GOP moderates worried that the leadership now puts them at risk—why make them take a risky vote on a bill unpopular in their districts if the Senate is going to strip out the provision?
Those who treat patients in safety net hospitals were reacting quickly to the deal-making.
"Eliminating commonsense requirements that private plans provide a minimum package of essential benefits [w]ould make this damaging bill even worse," Bruce Siegel of America's Essential Hospitals said in a statement. "It could leave countless people with too little coverage to meet their health care needs and drive higher rates of uncompensated care at hospitals already struggling to cover their costs."
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More